SCHEMBL2960950

SCHEMBL2960950

O=C(O)c1ccc(SC(F)(F)F)cc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
ALDH1A1 P00352 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
KCNK2 O95069 12/20 0.49
KCNK10 P57789 9/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 1/20 0.49
MAPK1 P28482 1/20 0.49
HTT P42858 1/20 0.49
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
ESR2 Q92731 1/20 0.47
KDM4E B2RXH2 1/20 0.47
PTPN1 P18031 1/20 0.47
HNF4A P41235 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9367905 0.86 MCL1 (0.61) TSHRALDH1A1CA12CA1CA2
SCHEMBL31319423 0.82 KCNK2 (0.49) TSHRALDH1A1KCNK2KCNK10MAPT
SCHEMBL23141266 0.81 KCNK2 (0.55) TSHRALDH1A1KCNK2KCNK10MAPT
SCHEMBL24616726 0.81 LMNA (0.59) TSHRALDH1A1KCNK2KCNK10MAPT
SCHEMBL2949448 0.79 ALDH1A1 (0.55) TSHRALDH1A1CA12CA1CA2
SCHEMBL15220064 0.79 ALDH1A1 (0.59) TSHRALDH1A1CA12CA1CA2
SCHEMBL11764782 0.78 KCNK2 (0.46) TSHRALDH1A1KCNK2KCNK10MAPT
SCHEMBL23141167 0.77 LMNA (0.51) TSHRALDH1A1KCNK2KCNK10MAPT
SCHEMBL22519100 0.77 MAPT (0.72) TSHRALDH1A1KCNK2KCNK10MAPT
SCHEMBL28028243 0.77 KCNK2 (0.45) TSHRALDH1A1KCNK2KCNK10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230161252-A1 POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-05-25 US disclosed
US-20230161252-A1 POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-05-25 US disclosed
US-7767665-B2 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-03 US disclosed
US-20090082343-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-03-26 US disclosed
US-7399759-B2 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-15 US disclosed
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-02-10 US disclosed
EP-1424336-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082343-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF MIF, MORF4L1, FOXM1 TSHR 1858/4885ALDH1A1 273/4885CA12 4849/4885
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof MIF, MORF4L1, FOXM1 TSHR 1858/4885ALDH1A1 273/4885CA12 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.